Al-Zoubi RM et al., 2026-10-15: 2026 review of antiparasitic drugs repurposed for oncology (ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole) summarising preclinical mechanisms including Wnt/beta-catenin, PI3K/Akt/mTOR, microtubule disruption and cancer stem cell targeting.
Ivermectin, a macrocyclic lactone, has shown potent activity against breast, ovarian, and colorectal cancer models through modulation of the P-glycoprotein drug efflux pump, activation of chloride ion channels, and inhibition of oncogenic signaling.
n/a (PubMed abstract)
Al-Zoubi RM et al., 2026-10-15: 2026 review of antiparasitic drugs repurposed for oncology (ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole) summarising preclinical mechanisms including Wnt/beta-catenin, PI3K/Akt/mTOR, microtubule disruption and cancer stem cell targeting. Study type: review.
